Age

18–70

Sex

ALL

Healthy volunteers

Not accepted

Patients who were diagnosed by the histologic, cytologic diagnosis of IV non-small cell lung cancer
Age from 18 to 70 years old
At least one target lesion diameter spiral CT ≥ 1 cm, or the common CT ≥ 2 cm, and can be measured by imaging tools
ECOG 0-1
Expected life time longer than 12 weeks
Normal laboratory values:
leucocyte≥ 4×109/L neutrophil≥ 1.5×109/L platelet≥100×109/L Hemoglobin≥ 10g/L ALT and AST ≤2.5×ULN (≤5×ULN if liver metastasis)

Patients have not used drugs according to protocol
Patients were allergic to pemetrexed or cisplatin
Patients received radiotherapy or other biological treatment 4 weeks before the trial
Uncontrolled hydrothorax or hydropericardium
neuropathy toxicity ≥ CTC 3
Severe symptomatic heart disease
Active upper gastrointestinal ulcer or digestive disfunction
Severe infection or metabolic disfunction
Patients with other malignant tumor
Uncontrolled brain metastases
Patients have accepted other clinical trials
Female patients during their pregnant and lactation period, or patients without contraception

Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients